Navigation Links
Tiny scaffolding allows stem cells to become working fat cells

g insulin-dependent, and lowering the likelihood they would develop type II diabetes," Kniss said.

He also suggested that the new approach might have commercial applications as a way of testing new drugs. "Small, three-dimensional cell colonies could be grown on multi-well assay plates and be used to test dozens of compounds at the same time," he explained.

"Since these cells better resemble how cells function in living tissue, they would offer a better test than current two-dimensional cell colonies provide." Kniss is currently working with an Ohio company to consider research on such new assay devices.


'"/>

Source:Ohio State University


Page: 1 2 3

Related biology news :

1. Microscopic scaffolding offers a simple solution to treating skin injuries
2. Bedsores and bald hides: Novel roles revealed for a scaffolding protein
3. Tissue engineered scaffolding allows reproduction of cartilage tissue
4. Researchers find how protein allows insects to detect and respond to pheromones
5. Enzyme allows B cells to resist death, leading to leukemia
6. Looks matter to female barn swallows
7. New law for resolution allows unprecedented sharpness in fluorescence microscopy
8. Stolen gene allows insect virus to enter cells
9. Researchers identify molecular anchor that allows bacterial invasion of central nervous system
10. Algal protein in worm neurons allows remote control of behavior by light
11. Why nerve cells work faster than the theory allows
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tiny scaffolding allows stem cells become working fat cells

(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... at the University of Georgia have discovered a central ... The misregulation of this switch may play a role ... the aggressiveness of tumors themselves. "Malignant cancer arises ... from their primary tissue location," said Natalia Starostina assistant ...
... BOSTON (December 7, 2010) Newly-created bioactive peptides promote ... and epithelial tissue, such as skin. These wound-healing peptides, ... in Wound Healing Research, increased angiogenesis in vitro by ... print this week in Wound Repair and Regeneration ...
... will meet again in So Paulo at the international ... to monitor new biodiversity conservation targets. The goal of ... for the conservation of biodiversity, as well as mechanisms ... event is organized by the Biota-FAPESP, the So Paulo ...
Cached Biology News:Study: mechanism that controls cell movement linked to tumors becoming more aggressive 2Study: mechanism that controls cell movement linked to tumors becoming more aggressive 3Bioactive peptides found to promote wound healing 2Bioactive peptides found to promote wound healing 3Biodiversity targets for the future 2Biodiversity targets for the future 3
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... 22, 2012 Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, today ... year ended December 31, 2011: Fourth Quarter ... million, compared to the $5.3 million for the fourth quarter ...
... The new Dynaflow Resolve System was ... to meet the demand for a simpler technology capable ... an advanced automated perfusion system that enables novel experimental ... using any cell type, and any compound. The new ...
... an inVentiv Health company and the leading management ... industry, today announced the launch of Encuity Research, ... a six-year veteran with Campbell Alliance, will serve ... be based in Newtown, PA. (Photo: ...
Cached Biology Technology:Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 2Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 3Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 4Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research 5